Antibodies to Endothelial Cells in Patients with Behçet's Disease

Aydintug, Ao.; Tokgöz, Güner; D’Cruz, D; Gürler, Aysel; Cervera, Ricard; Düzgün, Nurşen; Atmaca, L.S.; Khamashta, M. A.; Hughes, G. R. V.

doi:10.1006/clin.1993.1059

Cited by 96 publications

(34 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our laboratory results showed that BD patients with vasculitis, have particular biologic findings: accumulation of cytotoxic TCRg d + cells at the sites of inflammation, 7 high level of endothelin expression, 13 high autoantibodies against endothelial cells (AECA), 18 increased oxygen radical production, 19 high levels of cICAM-1, 20 and CD11/CD18 bearing lymphocytes in cerebrospinal fluid. 21 Most of these biological and immunological parameters have been described in various autoimmune and vasculitis conditions.…”

Section: Discussionmentioning

confidence: 75%

Levels of soluble Fas/APO‐1 in patients with Behçet′s disease

Hamzaoui

Zakraoui³

et al. 1998

Mediators of Inflammation

View full text Add to dashboard Cite

The aim of this study was to quantify soluble Fas/APO-1 (sFas/APO-1) protein in the serum of patients with Behcet's disease (BD) in active and inactive stages, compared with patients with systemic lupus erythematosus (SLE) and patients with rheumatoid arthritis (RA). Soluble Fas/APO-1 was quantified using a sandwich enzyme-linked immunosorbent assay. Increased serum sFas/APO-1 levels were observed in active BD, compared with inactive BD, RA patients and SLE patients. Increased serum sFas/APO-1 levels were correlated with the presence of neurologic manifestations or pulmonary involvement in active BD. In conclusion, increased levels of sFas/APO-1 occurred frequently and exclusively in active BD patients. Preliminary evidence suggested that elevated levels of sFas/APO-1 are associated with the clinical stage and clinical manifestations in BD.

show abstract

Section: Discussionmentioning

confidence: 75%

Levels of soluble Fas/APO‐1 in patients with Behçet′s disease

Hamzaoui

Zakraoui³

et al. 1998

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…50 Aydintug et al have also presented evidence of an association of the presence of AECAs and thrombosis in BD. 47 These data suggest that endothelial activation is responsible at least in part for the CNS manifestations of BD, denoting a more severe disease.…”

Section: Rheumatoid Arthritismentioning

confidence: 91%

Pathogenic role of anti-endothelial cell antibodies in autoimmune rheumatic diseases

Domiciano

Carvalho

Shoenfeld

2009

Lupus

View full text Add to dashboard Cite

Anti-endothelial cells antibodies have been detected in numerous autoimmune and inflammatory diseases, including systemic lupus erythematous, rheumatoid arthritis, vasculitis and sarcoidosis. Anti-endothelial cells antibodies bind to endothelial cell antigens and induce endothelial damage. Their effects on the endothelial cell have been considered responsible, at least in part, by the vascular injury which occurs in these pathological conditions.

show abstract

“…However, the exact role of these antibodies in the disease has not been clarified. [83][84][85] Endothelial cell antibodies were detected in 18-37% of patients with BD. 86,87 However, others have not found any statistically significant difference between patients and controls.…”

Section: Superior Vena Cava Thrombosismentioning

confidence: 99%

Behçet’s disease: an update on pathogenesis, diagnosis and management of vascular involvement

Kaklamanis

Calamia

2010

Rheumatol Rep

View full text Add to dashboard Cite

The objective of this review is to summarize reports of the prevalence, clinical presentation, diagnostic methodology and treatment of vasculitic manifestations of Behçet’s disease (BD). We performed a literature search on vasculitis in BD. Articles were selected which provided insight into the pathogenesis and clinical aspects of vasculitis. Vasculitis underlies many of the clinical features of BD. Small vessel vasculitis is often found in the pathology of the mucocutaneous manifestations of BD. Large vessel vasculitis has been reported in 15-40% of BD patients. Ultrasound, angiography and tomography are applied to confirm the diagnosis when venous involvement is suspected. Endothelial dysfunction plays a role in the pathogenesis of disease. Peripheral arterial involvement in BD occurs in the form of arterial occlusion or aneurysms. Pulmonary arterial involvement is often life-threatening. The cause of cardiac vascular involvement requires an aggressive diagnostic approach. Corticosteroids and immunosuppressive agents have been used successfully in the early stage of large vessel disease and should be used as an adjunct to surgery. An increasing amount of data is available regarding the role of anti-tumor necrosis factor (TNF) agents for the treatment of BD. Anticoagulant therapy may be hazardous in patients with aneurysmal dilatation of the pulmonary vascular tree and is not effective in the treatment of venous thrombosis. Inflammation of small and large vessels is very frequent in BD. Both arteries and veins may be involved. Early recognition and appropriate management of large vessel vasculitis in BD is essential to reduce associated morbidity and mortality

show abstract

Antibodies to Endothelial Cells in Patients with Behçet's Disease

Cited by 96 publications

References 0 publications

Levels of soluble Fas/APO‐1 in patients with Behçet′s disease

Levels of soluble Fas/APO‐1 in patients with Behçet′s disease

Pathogenic role of anti-endothelial cell antibodies in autoimmune rheumatic diseases

Behçet’s disease: an update on pathogenesis, diagnosis and management of vascular involvement

Contact Info

Product

Resources

About